scholarly journals Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects

ACS Nano ◽  
2018 ◽  
Vol 12 (8) ◽  
pp. 7663-7681 ◽  
Author(s):  
Zhenshan Jia ◽  
Xiaobei Wang ◽  
Xin Wei ◽  
Gang Zhao ◽  
Kirk W. Foster ◽  
...  
Keyword(s):  
Side Effects ◽  
Glucocorticoid Side Effects

scholarly journals Prevention and treatment of systemic glucocorticoid side effects

2010 ◽  
Vol 49 (3) ◽  
pp. 239-248 ◽  
Author(s):  
Siamak Moghadam-Kia ◽  
Victoria P. Werth
Keyword(s):  
Side Effects ◽  
Systemic Glucocorticoid ◽  
Prevention And Treatment ◽  
Glucocorticoid Side Effects

scholarly journals Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community

BMJ Open ◽  
2017 ◽  
Vol 7 (4) ◽  
pp. e014603 ◽  
Author(s):  
Ruth Costello ◽  
Rikesh Patel ◽  
Jennifer Humphreys ◽  
John McBeth ◽  
William G Dixon
Keyword(s):  
Side Effects ◽  
Patient Perceptions ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Online Health Community ◽  
Health Community ◽  
Glucocorticoid Side Effects

scholarly journals 209. PATIENT PERCEPTIONS OF GLUCOCORTICOID SIDE EFFECTS: A SURVEY OF USERS IN AN ONLINE HEALTH COMMUNITY

Rheumatology ◽  
2017 ◽  
Vol 56 (suppl_2) ◽  
Author(s):  
Ruth Costello ◽  
Rikesh Patel ◽  
Jennifer Humphreys ◽  
John McBeth ◽  
William Dixon
Keyword(s):  
Side Effects ◽  
Patient Perceptions ◽  
Online Health Community ◽  
Health Community ◽  
Glucocorticoid Side Effects

Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid‐induced leucine zipper? A perspective

2014 ◽  
Vol 28 (12) ◽  
pp. 5055-5070 ◽  
Author(s):  
Emira Ayroldi ◽  
Antonio Macchiarulo ◽  
Carlo Riccardi
Keyword(s):  
Side Effects ◽  
Glucocorticoid Receptor ◽  
Leucine Zipper ◽  
Receptor Modulator ◽  
Glucocorticoid Side Effects

scholarly journals Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2368-2368
Author(s):  
Shayi Jiang ◽  
Eric S. Sandler ◽  
Hui Jiang
Keyword(s):  
Side Effects ◽  
Intravenous Immunoglobulin ◽  
Response Rate ◽  
Complete Response Rate ◽  
Complete Response ◽  
Severe Thrombocytopenia ◽  
Newly Diagnosed ◽  
Older Children ◽  
Significant Difference ◽  
Glucocorticoid Side Effects

Objective: Children with immune thrombocytopenia (ITP) are mostly self-limited, so they are usually observed closely and not need treatment in the clinical work. However, for children with platelet<10×109/L or platelet <20×109/L accompanied with obvious hemorrhagic tendency, intravenous immunoglobulin (IVIG) combined with glucocorticoids is commonly used on prevent severe bleeding. The purpose of this study is to investigate whether glucocorticoids are required at the same time in ITP children who need intravenous gamma globulin to rapidly increase platelet level. Method: 210 newly diagnosed ITP children with severe thrombocytopenia (platelet <20×109/L with obvious bleeding tendency) were randomly assigned to the non-glucocorticoid group and glucocorticoid group. The former was treated with IVIG alone, while the latter was treated with a combination of IVIG and glucocorticoid. Then each group was further divided into the infant group (<1 year old) and the older children group (≥1 year old). Clinical index such as complete response rate, relapse rate, duration of therapy and glucocorticoid side effects were analyzed and compared in each group. Results: ①The complete response rate showed no statistically differences (P>0.05) among the non-glucocorticoid infant group (95.65%) and glucocorticoid infant group (92.50%), but significant differences in the older children groups with or without glucocorticoid (100% vs 92.31%, χ²=4.720, P=0.03). ②Regard the relapse rate, it was statistically lower in non-glucocorticoid infant group than in non-glucocorticoid older children group (10.41% vs 53.35%, χ²=21.685, P<0.001); in the glucocorticoid older children group than in the non-glucocorticoid older children group (21.05% vs 53.45%, χ²=12.888, P <0.001). No statistical significance was proved among glucocorticoid infant group and non-glucocorticoid infant group (12.5% vs 10.41%, P>0.05). ③After treatment for 72 h, There was no significant difference in the number of children with the platelet count >50×109/L between glucocorticoid group and non-glucocorticoid group. ④There was a significant difference for the duration of therapy between the non-glucocorticoid group (4d) and glucocorticoid group (2 months)(Ζ=-7.430, P<0.001). ⑤32.5% patients of the glucocorticoid infant group suffered from infections, that was higher than in the non-glucocorticoid infant group(11.63%), and there was marked significance(χ²=7.031, P=0.008). The incidence of Cushing's syndrome in the infant glucocorticoid group (42.5%) was as the same as that in the older children glucocorticoid group (36.84%). No corticosteroid-related side effects were observed in all non-glucocorticoid groups. Conclusions: Intravenous immunoglobulin (IVIG) is accepted as an effective treatment for newly diagnosed infant ITP with platelet counts<20×109/L, combination with glucocorticoid provided no significant benefit for the complete response and preventing relapse, on the contrary, may lead to high risk for infections and increasing glucocorticoid side-effects. IVIG combined with glucocorticoid can make significant clinical efficacy improvement in the older children group. Key words: Immune thrombocytopenia; Intravenous immunoglobulin; glucocorticoid; Children; Relapse Disclosures No relevant conflicts of interest to declare.

Gastric Ulcers Produced by Cisplatin

1981 ◽  
Vol 39 ◽  
pp. 582-583
Author(s):  
S.K. Aggarwal ◽  
J. San Antonio
Keyword(s):  
Electron Microscopy ◽  
Single Dose ◽  
Side Effects ◽  
Antitumor Agent ◽  
Gastric Ulcers ◽  
Enzyme Cytochemistry ◽  
Intestinal Toxicity ◽  
Ovarian Cancers ◽  
Inner Surface

Cisplatin (cis-dichlorodiammineplatinum(II)) a potent antitumor agent is now available for the treatment of testicular and ovarian cancers. It is however, not free from its serious side effects including nephrotoxicity, gastro intestinal toxicity, myelosuppression, and ototoxicity. Here we now report that the drug produces peculiar bloating of the stomach in rats and induces acute ulceration.Wistar-derived rats weighing 200-250 g were administered cisplatin(9 mg/kg) ip as a single dose in 0.15 M NaCl. After 3 days the animals were sacrificed by decapitation. The stomachs were removed, the contents analyzed for pepsin and acidity. The inner surface was examined with a dissecting microscope after a moderate stretching for ulcers. Affected areas were fixed and processed for routine electron microscopy and enzyme cytochemistry.The drug treated animals kept on food and water consistently showed bloating and lesions (Fig. 1) with a frequency of 6-70 ulcers in the rumen section of the stomachs.

Sign in / Sign up

Export Citation Format

Share Document